Facebook
Twitter
LinkedIn
Forward
This session will inform HCPs on the tirzepatide molecule, design of the SURMOUNT global trial program for the treatment of obesity and overweight, and safety and efficacy data disclosure for SURMO
|
In adolescents and adults, the co-occurrence of eating disorders and overweight or obesity is continuing to increase.
|
Obesity is a complex phenotype reflecting the interactions of numerous genes that have been “selected” for in service of reproductive integrity with modern environments.
|
Intermittent Fasting (IF) as a means of dietary modification has gained popularity among individuals with obesity as a means of achieving weight loss.
|
Individual patient response to nutritional therapies varies widely.
|
*There is a printed version of this product available in the OMA store
|
The OMA SAP is a comprehensive self-exam containing 261 questions of multiple choice and matching questions regarding the science and clinical aspects of obesity. The set of questions is followed b
|
Lifestyle Therapeutics in Obesity Medicine Certificate Program
|
The AAP has comprehensively updated their recommendations regarding the disease of obesity in childhood. The incidence of obesity in childhood has not improved.
|
Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed.
|